Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development
China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...
Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics
A new bar was set for the most valuable out-license deal struck by a China-based...
Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology
Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series...
Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...
NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions
The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe
Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...
Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting
The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...
United Family Healthcare Partners with HSS for Orthopedic Collaboration
United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...
MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...